Cadrenal Therapeutics, Inc.

For the period ended Dec 31, 2025. Filed Mar 31, 2026.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2025 · Filed Mar 31, 2026

CVKD$1.44+5.1%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Balance Sheets at December 31, 2025 and 2024

BALANCE SHEETS

	December 31,	December 31,
	2025	2024
Assets:
Current assets:
Cash and cash equivalents	$4,007,789	$10,017,942
Interest receivable	5,096	38,153
Prepaid expenses and other current assets	200,140	42,257
Deferred offering costs	106,342	14,445
Total current assets	4,319,367	10,112,797
Property, plant and equipment, net	5,174	6,944
Other assets	2,167	3,792
Total assets	$4,326,708	$10,123,533
Liabilities and Stockholders' Equity:
Current liabilities:
Accounts payable	$650,663	$1,502,468
Accrued liabilities	937,319	1,181,490
Total current liabilities	1,587,982	2,683,958
Total liabilities	1,587,982	2,683,958
Stockholders’ equity:
Preferred stock, $0.001 par value, 7,500,000 shares authorized, no shares issued and outstanding as of December 31, 2025 and 2024	-	-
Common stock, $0.001 par value; 75,000,000 shares authorized, 2,338,127 shares issued and outstanding as of December 31, 2025; 1,782,486 shares issued and outstanding as of December 31, 2024	2,338	1,782
Additional paid-in capital	41,696,533	33,160,576
Accumulated deficit	(38,960,145)	(25,722,783)
Total stockholders’ equity	2,738,726	7,439,575
Total liabilities and stockholders’ equity	$4,326,708	$10,123,533

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.